Standard BioToolsLAB
About: Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Employees: 818
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
5% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 40
0% more funds holding
Funds holding: 140 [Q3] → 140 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 22
1.04% less ownership
Funds ownership: 75.54% [Q3] → 74.5% (-1.04%) [Q4]
10% less capital invested
Capital invested by funds: $541M [Q3] → $485M (-$55.7M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
93% less call options, than puts
Call options by funds: $12K | Put options by funds: $178K
Research analyst outlook
We haven’t received any recent analyst ratings for LAB.
Financial journalist opinion









